Continuous glucose monitoring: current clinical use
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data
OpenAlex W2097539206 · doi:10.1002/dmrr.2346
What was done
This is a narrative review describing the clinical indications, technical features, and evidence base for four subcutaneous continuous glucose monitoring (CGM) systems available in 2012. No systematic search protocol, statistical synthesis, or primary cohort data are reported in the abstract.
What was found
The abstract reports no numerical metrics or effect sizes. It qualitatively notes that CGM helps lower HbA1c without increasing severe hypoglycemia in type 1 diabetes, but lacked sufficient evidence to support its use for preventing severe hypoglycemia or managing type 2 diabetes as of 2012.
Why it matters
It summarizes the early clinical landscape and technological rationale for using continuous glucose monitoring to address glycemic variability beyond standard HbA1c monitoring.
Limits
The paper is a non-systematic narrative overview with no primary data or quantitative findings. Evidence and technology reflect the state of diabetes care in 2012.
Cited by
- supports Continuous glucose monitors collect data at 5-minute intervals.